



GOVERNOR'S OFFICE OF  
BUDGET AND PROGRAM PLANNING

## Fiscal Note 2013 Biennium

**Bill #** HB0615

**Title:** Advance cancer research and treatment

**Primary Sponsor:** Williams, Kathleen

**Status:** As Introduced

- Significant Local Gov Impact     
 Needs to be included in HB 2     
 Technical Concerns  
 Included in the Executive Budget     
 Significant Long-Term Impacts     
 Dedicated Revenue Form Attached

### FISCAL SUMMARY

|   | <u>FY 2012<br/>Difference</u> | <u>FY 2013<br/>Difference</u> | <u>FY 2014<br/>Difference</u> | <u>FY 2015<br/>Difference</u> |
|---|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
| <b>Expenditures:</b>                    |                               |                               |                               |                               |
| General Fund                            | \$14,000                      | \$0                           | \$0                           | \$0                           |
| <b>Revenue:</b>                         |                               |                               |                               |                               |
| General Fund                            | \$0                           | \$0                           | \$0                           | \$0                           |
| <b>Net Impact-General Fund Balance:</b> | <u>(\$14,000)</u>             | <u>\$0</u>                    | <u>\$0</u>                    | <u>\$0</u>                    |

**Description of fiscal impact:** If passed this bill will have a fiscal impact of \$14,000 on the general fund. The impact will include costs for travel, communications, and printing the report to be presented to the interim committee.

### FISCAL ANALYSIS

#### Assumptions:

#### **State Auditor's Office (SAO)**

1. If this bill is passed the insurance commissioner shall review and facilitate appropriate and equitable treatment of cancer patients eligible for clinical trials by offerors of health insurance coverage in Montana.
2. The insurance commissioner shall convene an advisory committee of representatives of insurance, reinsurance, and self-insurance offerors in Montana, as well as patients, health care advisors, providers, and administrators, that will meet to evaluate the causes of the routine care coverage details of ineligibilities for insureds recommended for participation in cancer trials.
3. The advisory committee will prepare a final report summarizing their findings and present the report to the interim committee on or before March 31, 2012.

- HB 615 provides a \$14,000 general fund appropriation to carry out the provisions of the bill. The SAO estimates expenditures of \$8,000 for travel, \$1,000 for communications, and \$5,000 for printing/reports.

**Legislative Branch**

- As required by the bill, the Children, Families, Health and Human Services Interim Committee will coordinate with the insurance commissioner and dedicate committee time to consideration of a report prepared by the commissioner and the advisory committee created under the bill. The committee will consider legislation or take other actions in response to the report during the ordinary course of committee business.
- There is no fiscal impact to the Legislative Branch.

|   | <u>FY 2012</u><br><u>Difference</u> | <u>FY 2013</u><br><u>Difference</u> | <u>FY 2014</u><br><u>Difference</u> | <u>FY 2015</u><br><u>Difference</u> |
|---|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| <b><u>Fiscal Impact:</u></b>  |                                     |                                     |                                     |                                     |
| <b><u>Expenditures:</u></b>   |                                     |                                     |                                     |                                     |
| Operating Expenses  | <u>\$14,000</u>                     | <u>\$0</u>                          | <u>\$0</u>                          | <u>\$0</u>                          |
| <b>TOTAL Expenditures</b>   | <b><u>\$14,000</u></b>              | <b><u>\$0</u></b>                   | <b><u>\$0</u></b>                   | <b><u>\$0</u></b>                   |
| <b><u>Funding of Expenditures:</u></b>  |                                     |                                     |                                     |                                     |
| General Fund (01)   | <u>\$14,000</u>                     | <u>\$0</u>                          | <u>\$0</u>                          | <u>\$0</u>                          |
| <b>TOTAL Funding of Exp.</b>  | <b><u>\$14,000</u></b>              | <b><u>\$0</u></b>                   | <b><u>\$0</u></b>                   | <b><u>\$0</u></b>                   |
| <b><u>Revenues:</u></b>   |                                     |                                     |                                     |                                     |
| <b>TOTAL Revenues</b>   | <b><u>\$0</u></b>                   | <b><u>\$0</u></b>                   | <b><u>\$0</u></b>                   | <b><u>\$0</u></b>                   |
| <b><u>Net Impact to Fund Balance (Revenue minus Funding of Expenditures):</u></b> |                                     |                                     |                                     |                                     |
| General Fund (01)   | (\$14,000)                          | \$0                                 | \$0                                 | \$0                                 |

\_\_\_\_\_  
*Sponsor's Initials*

\_\_\_\_\_  
*Date*

\_\_\_\_\_  
*Budget Director's Initials*

\_\_\_\_\_  
*Date*